{
    "nctId": "NCT02028494",
    "briefTitle": "Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer",
    "officialTitle": "Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 350,
    "primaryOutcomeMeasure": "Progress Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1 Subject Inclusion Criteria\n\n  * Informed consent has been obtained.\n  * Metastatic breast cancer.\n  * Measurable or non-measurable disease per RECIST criteria.\n  * Pathologic confirmation of breast cancer.\n  * No limit to the number of prior chemotherapy regimens permitted for metastatic disease.\n  * At least 3 weeks since prior chemotherapy. Patients should have recovered from all acute toxicity from such therapy (excluding alopecia).\n  * Age \u226518.\n  * ECOG 0-2\n  * Absolute Neutrophil Count (ANC )\u22651.0; hemoglobin \u22659, platelets\n\n    \u226575.000\n  * AST, ALT and Alkaline phosphatase \\<2.5x upper limit of normal (or \\<5x upper limit of normal in the case of liver metastases). Total bilirubin \\<1.5x upper limit of normal.\n  * Estimated creatinine clearance \\>50ml/min.\n  * If female of childbearing potential, pregnancy test is negative and the patient agrees to use an effective method to avoid pregnancy during the study.\n\nExclusion Criteria:\n\n* HER2 over-expression and/or amplification as determined by immunohistochemistry (3+) or FISH (\\>2.0).\n\n  * No prior fluoropyrimidine in the metastatic setting. Adjuvant fluoropyrimidine is permitted if \\>12 months have elapsed since treatment.\n  * No restriction for prior hormonal therapy.\n  * GI malabsorption syndrome which could impair oral drug absorption.\n  * Concurrent use of warfarin is discouraged as drug interactions may make management of INR more difficult.\n  * Central nervous system metastases are permitted if previously treated or clinically stable for at least 3 months.\n  * Pregnant or nursing patients.\n  * Life expectancy \\<3 months.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}